Analysguiden lowers the fair value for Vaxxa to SEK 0.95 per share from the previous SEK 1.06, mainly due to a higher required rate of return, according to a commissioned analysis.At the same time, revenue forecasts are raised slightly and the company is expected to enter a more mature phase with lower development costs, which in the long term can improve margins and be a clear trigger for a revaluation. To regain the market’s confidence, the need for clearer financial communication, better forecast accuracy and possible insider purchases is highlighted.